宜明昂科生物医药技术（上海）股份有限公司（股票名称：宜明昂科-B，股票代码：01541）于2026年7月17日公告，显示公司当日于香港联交所场内回购H股6.38万股，占当日现有已发行股份（不包括库存股）约0.0152%。本次回购每股价格介乎港币3.39港元至3.59港元，回购总金额约22.04万港元。
公告显示，本次回购完成后，公司已发行股份（不包括库存股）数量变为418,626,905股，库存股数上升至1,850,400股，合计420,477,305股。本次股份购回基于公司2026年5月28日通过的购回授权，该授权可回购的股份总数为43,150,769股。截至目前，公司已依据该授权累计在香港联交所或其他证券交易所回购1,850,400股，占授权生效当日已发行股份总数约0.429%。
公司确认，本次回购已根据香港联交所证券上市规则及相关法律规定进行。公告由执行董事、联席公司秘书关梅签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.